CalciMedica (NASDAQ: CALC) faces Nasdaq market value and $1 bid price breaches
CalciMedica (NASDAQ: CALC) has received two notices from Nasdaq for non-compliance, specifically for its market value of listed securities falling below $35 million and its common stock trading below the $1 minimum bid price for 30 consecutive business days. The company has 180 calendar days for each deficiency, until September 9, 2026, for market value and September 14, 2026, for bid price, to regain compliance through various alternatives, including a possible reverse stock split. Failure to do so could result in delisting from the Nasdaq Capital Market.
How this was made
The 30-second read
Why it matters
Failure to regain compliance could lead to delisting, negatively impacting shareholders and liquidity.
Market read
The news is highly relevant for investors holding or considering CalciMedica shares, especially in the biotech sector.
What to watch
Potential for a strategic reverse split or other measures to restore compliance and stabilize the stock.
Background
CalciMedica has been notified by Nasdaq for non-compliance related to market value and bid price requirements, risking delisting if issues are not resolved within specified deadlines.
Ticker impact
High relevance due to direct impact on company's listing status and market value.
Short-term decline expected if delisting fears intensify; potential rebound if the company successfully regains compliance.
The breach of Nasdaq listing requirements introduces uncertainty, likely causing short-term negative price movement. The outcome depends on the company's corrective measures.
Market effects
Potential negative sentiment for biotech and life sciences sectors due to regulatory and compliance concerns.
Limited regional impact; primarily affects Nasdaq-listed biotech firms.
Low; specific to Nasdaq-listed company.
Counterpoint
The company might successfully address the compliance issues, leading to a rebound in stock price.
Key entities
- CompanyCalciMedica
A biotech firm listed on NASDAQ facing compliance issues.





